Month: May 2022

Technology is first of its kind for powering the 1-100 milliampere-hour  class of connected consumer, health and IoT sensor devices Ensurge Micropower (OSE: ENSU, and OTCIQ: ENMPY), today announced it has filed several provisional patent applications for its solid-state lithium battery technology. The proprietary technology is the first of its kind that will enable 1-100 milliampere-hour (mAh) rechargeable microbattery products with the energy density, customizable form factors, charging speed and high-volume manufacturability to power a new generation of connected devices. “Ensurge’s patent filings represent innovations developed over the past two years by our cross-functional teams as they addressed some of the microbattery industry’s most difficult engineering and manufacturing challenges including dense cell architecture, ultrathin...

The Supervisory Board of AS Harju Elekter decided on May 20th, 2022, to appoint Risto Vahimets as the new member of the Audit Committee and Andres Toome as the chairman of the Audit Committee. The Audit Committee will continue with three members: Andres Toome (chairman), Triinu Tombak and Risto Vahimets. Harju Elekter is an international industrial group with more than 50 years of experience, whose main activity is the development and production of electrical and automation equipment. Part of the technical solutions of Harju Elekter are aimed at the renewable energy sector, offering complete plans for solar power plants, electric vehicle charging stations, and other related solutions. Its factories in Estonia, Finland, Sweden, and Lithuania employ approximately 900 employees, and the Group’s revenue for Q1 2022 was 37,3 million euros....

Ad hoc announcement pursuant to Art. 53 LRAprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns Primary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoring Idorsia to host an investor webcast to discuss PRECISION top-line results tomorrow May 24 at 14:00hrs CESTAllschwil, Switzerland – May 23, 2022Idorsia Ltd (SIX: IDIA) today announced positive top-line results of PRECISION, the Phase 3 study investigating aprocitentan, Idorsia’s dual endothelin receptor antagonist, for the treatment of patients whose blood pressure is not adequately...